139 related articles for article (PubMed ID: 9354926)
1. Biomarker end-points in cancer chemoprevention trials.
Boone CW; Kelloff GJ
IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
[TBL] [Abstract][Full Text] [Related]
2. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
4. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
5. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
6. Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis.
Boone CW; Kelloff GJ
Cancer Surv; 1998; 32():133-47. PubMed ID: 10489626
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
8. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
[TBL] [Abstract][Full Text] [Related]
9. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.
Boone CW; Kelloff GJ
J Cell Biochem Suppl; 1994; 19():10-22. PubMed ID: 7823580
[TBL] [Abstract][Full Text] [Related]
10. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
11. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
12. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
13. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
[TBL] [Abstract][Full Text] [Related]
14. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents.
Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
J Cell Biochem Suppl; 1997; 28-29():1-20. PubMed ID: 9589346
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
[TBL] [Abstract][Full Text] [Related]
16. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention with theaflavins of rat esophageal intraepithelial neoplasia quantitatively monitored by image tile analysis.
Boone CW; Stoner GD; Bacus JV; Kagan V; Morse MA; Kelloff GJ; Bacus JW
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1149-54. PubMed ID: 11097221
[TBL] [Abstract][Full Text] [Related]
18. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
Marshall JR
IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
[TBL] [Abstract][Full Text] [Related]
19. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy.
Boone CW; Kelloff GJ; Steele VE
Cancer Res; 1992 Apr; 52(7):1651-9. PubMed ID: 1551096
[TBL] [Abstract][Full Text] [Related]
20. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials.
Fabian CJ; Zalles C; Kamel S; Zeiger S; Simon C; Kimler BF
J Cell Biochem Suppl; 1997; 28-29():101-10. PubMed ID: 9589354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]